Small-molecule inhibitors of tyrosine kinases (TKIs) are the mainstay of treatment for many
malignancies and represent novel treatment options for other diseases such as idiopathic …

The introduction of imatinib (IM), a BCR-ABL1 tyrosine kinase inhibitor (TKI), has
represented a significant advance in the first-line treatment of chronic myeloid leukemia …

Background The advanced phases of chronic myeloid leukemia (CML) are known to be
more resistant to therapy. This resistance has been associated with the overexpression of …

Imatinib has so far been the first-choice treatment in chronic myeloid leukemia with excellent
results. However, only a proportion of patients achieve major molecular response–hence the …

Epidermal growth factor receptor (EGFR) is a transmembrane protein commonly targeted by
tyrosine kinase inhibitors (TKIs) as a front-line therapy for patients with many cancers …

Although the prognosis of chronic myeloid leukemia (CML) patients treated with imatinib is
good, many fail to develop an optimal response or lose one. This heterogeneity could be …

Imatinib is a highly effective therapy for chronic phase-chronic myeloid leukaemia (CP-CML)
patients; however, responses to frontline imatinib are variable. The human organic cation …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm, characterized by the
unrestrained expansion of pluripotent hematopoietic stem cells. CML was the first …

A major difficulty in the treatment of cancers is the poor response of many tumors to
pharmacological regimens. This situation can be accounted for by the existence of a variety …

Background The polyspecific organ cation transporter 1 (OCT1) is one of the most important
active influx pumps for drugs like the kinase inhibitor sorafenib. The aim of this retrospective …